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Structure of Schlafen13 reveals a new class
of tRNA/rRNA- targeting RNase engaged
in translational control
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Cleavage of transfer (t)RNA and ribosomal (r)RNA are critical and conserved steps of
translational control for cells to overcome varied environmental stresses. However, enzymes
that are responsible for this event have not been fully identified in high eukaryotes. Here, we
report a mammalian tRNA/rRNA-targeting endoribonuclease: SLFN13, a member of the
Schlafen family. Structural study reveals a unique pseudo-dimeric U-pillow-shaped archi-
tecture of the SLFN13 N′-domain that may clamp base-paired RNAs. SLFN13 is able to digest
tRNAs and rRNAs in vitro, and the endonucleolytic cleavage dissevers 11 nucleotides from the
3′-terminus of tRNA at the acceptor stem. The cytoplasmically localised SLFN13 inhibits
protein synthesis in 293T cells. Moreover, SLFN13 restricts HIV replication in a nucleolytic
activity-dependent manner. According to these observations, we term SLFN13 RNase S13.
Our study provides insights into the modulation of translational machinery in high eukar-
yotes, and sheds light on the functional mechanisms of the Schlafen family.
DOI: 10.1038/s41467-018-03544-x OPEN
1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou
510060, Guangdong, China. 2 State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510060, Guangdong, China.
3 Laboratory for Functional Genomics and Systems Biology, Berlin Institute for Medical Systems Biology, Berlin 13125, Germany. 4Department of Biology,
Southern University of Science and Technology, Shenzhen 518055, Guangdong, China. 5 Key Laboratory of Tropical Disease Control of Ministry of Education,
Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, Guangdong, China. 6Medi-X Institute, SUSTech
Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China. 7Present address:
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA. 8Present address:
Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg 69120, Germany. These authors contributed equally: Jin-Yu Yang and
Xiang-Yu Deng. Correspondence and requests for materials should be addressed to W.X. (email: xiewei6@mail.sysu.edu.cn)
or to S.G. (email: gaosong@sysucc.org.cn)
NATURE COMMUNICATIONS |  (2018) 9:1165 | DOI: 10.1038/s41467-018-03544-x |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Modulation of translational machinery is a critical strat-egy for cells to overcome varied environmental assaultsincluding viral infections1–4. Known mechanisms
involve the intervention with eukaryotic translation initiation
factor 4F complex (eIF4F complex) or eIF2–GDP, which pro-
motes the formation of so-called stress granules and eventually
causes rapid inhibition of bulk protein synthesis1,5. Besides the
regulation of translation initiation, the turnover of tRNA and
rRNA has also been suggested to play an important role in
translational control6–8. Stress-induced cleavage of tRNA and
rRNA in the cytosol is observed in both prokaryotes and eukar-
yotes, which causes protein synthesis arrest and results in growth
inhibition or eventually, cell death8–10. In addition, emerging
evidence suggests that the cleavage products of tRNA and rRNA
may act as siRNA or miRNA in promoting translation inhibi-
tion11–13. Up to now, few tRNases involved in this process are
known in high eukaryotes. These enzymes, such as human
angiogenin, are normally secreted or sequestered proteins that
gain access to cytosolic tRNAs upon cellular stress8,14,15. More
RNases responsible for stress-induced tRNA/rRNA turnover are
yet to be identified.
Schlafen proteins (SLFNs) were first discovered in regulating
mice thymocyte development16, and then found to span across
mammals with great diversity17. There are ten known or pre-
dicted SLFNs in mice which can be categorised into three sub-
groups by size, whereas only five SLFNs have been identified in
humans, and four of them (SLFN5, SLFN11, SLFN13 and
SLFN14) belong to the largest subgroup III17 (Supplementary
Fig. 1a). SLFNs were reported to be interferon (IFN)-inducible18–
21, and their functions have been implicated in various biological
processes including cell differentiation, tumour suppression,
immune response regulation and the restriction of viruses22.
Specifically, human SLFN11 has been reported to bind tRNAs
and restrict HIV protein synthesis possibly by means of codon-
bias discrimination23. However, the detailed structural properties
and functional mechanisms of SLFNs still remain unclear.
All SLFNs share a specific N-terminal AAA_4 domain
(Pfam04326, termed N′-domain in this paper) which has a very
limited sequence homology to other known proteins17 and was
reportedly involved in tRNA manipulation for certain mem-
bers23,24. In addition, a SWADL domain is present in the members
of subgroups II and III, and the largest SLFN subgroup is char-
acterised by a C-terminal region that is homologous to the super-
family I of RNA helicases25 (Supplementary Fig. 1a). To gain a
functional insight into the Schlafen family, we determined the
crystal structure of SLFN13′s N′-domain. Investigation of the
structure and subsequent functional analysis reveals that SLFN13 is
a novel tRNA/rRNA-targeting RNase with potent anti-HIV activity.
These results expand our vision of translational control in high
eukaryotes and functional mechanisms of the Schlafen family.
Results
Overall structure of the SLFN13 N′-domain. The structure of rat
(r)SLFN13 (related to human [h]SLFN13 and mouse [m]SLFN8) N
′-domain containing residues 14–353 was solved at 3.18 Å, where
the anomalous signals of 31 selenium atoms in the asymmetric unit
were used for phasing. In the calculated electron density, the main
chains and most side chains were clearly traceable, enabling us to
unambiguously assign them. The final model was refined to an Rfree
of 0.247 (Table 1, Fig. 1a, b; Supplementary Fig. 1b). 15 vector-
encoded residues fused N-terminally to rSLFN1314–353 are clearly
discernable in the model. The U-pillow-shaped rSLFN1314–353 is
composed of an N-terminal lobe (N-lobe), a C-terminal lobe
(C-lobe) and a bridging domain (BD), which together create a huge
valley with a width of ~23 Å and a depth of ~20 Å. rSLFN1314–353
exhibits a pseudo-dimeric organisation: each lobe contains a four-
stranded β-sheet surrounded by three α-helices, and the bipartite
BD derived from two separate regions of the primary sequence also
bears a two-fold symmetry in topology (Fig. 1b, c; Supplementary
Fig. 1c).
The α2N and α2C of the two lobes individually wedge into the
grooves of the butterfly-like BD at both sides (Fig. 1b). N-lobe-BD
association includes a hydrogen bond between Asn54 of α2N and
the backbone oxygen of Cys125, as well as a carboxylate-π-
stacking between Glu47 of α2N and Trp328 of β2Β (Fig. 1d).
Corresponding associations were found at equivalent positions of
C-lobe-BD interface (Asn236-Val320O and Glu229-Tyr132),
although an extra salt bridge between Glu210 and Arg134 is also
present (Fig. 1e). Moreover, a bulging loop of C-lobe is tightly
associated with BD by a line of main chain hydrogen bonds and a
CCCH-type zinc finger (Fig. 1f; Supplementary. 1d). Mutation on
any of the Zn2+-coordinating residue rendered rSLFN131–353
insoluble, suggesting that the zinc finger is crucial for the folding
of rSLFN13. rSLFN131–353 constructs were eluted as monomers in
the right-angle light scattering (RALS) analysis, whereas the
crystallised His6-tagged rSLFN1314–353 was a dimer (Supplemen-
tary Fig. 2a). The dimerisation of His6-tagged rSLFN1314–353 is
likely mediated by the artificial N-terminus (Supplementary
Fig. 2b). In agreement with this, His6-tagged rSLFN1314–353
showed much higher resistance to the proteolytic treatment
targeting His6-tag compared to His6-tagged rSLFN131–353
(Supplementary Fig. 2c). In this paper, the N′-domain constructs
of SLFN13 are collectively termed SLFN13-N unless otherwise
specified. The same nomenclature is also applied to other SLFNs.
SLFN13 N′-domain cleaves tRNA in vitro. Close relatives of
SLFN13 were reported to functionally associate with tRNA23,24,
but the detailed mechanism has not been characterised yet. To
understand whether and how SLFN13 is involved in tRNA
Table 1 Crystallographic data collection and refinement
statistics
rSLFN1314–353 rSLFN1314–353
Data collection
Data set Native SeMet derivative
Space group C2 C2
Cell dimensions
a, b, c (Å) 172.05, 134.33, 77.66 171.96, 134.65, 77.69
α, β, γ (°) 90, 105.51, 90 90, 104.72, 90
Wavelength (Å) 0.97853 0.97931
Resolution (Å) 50.0–3.18 (3.38–3.18)a 50.0–3.50 (3.71–3.50)
Rsym 0.049 (0.544) 0.086 (0.525)
I/σI 17.08 (2.05) 12.00 (2.81)
Completeness (%) 99.2 (98.4) 99.4 (99.3)
Redundancy 3.41 (3.36) 3.84 (3.87)
Refinement
Resolution (Å) 35.24–3.18 (3.30–3.18)
No. reflections 28,212 (2660)
Rwork/Rfree 0.200/0.247
Average B-factor 108.67
R.m.s. deviations
Bond lengths (Å) 0.003
Bond angles (°) 0.635
Ramachandran plot
(%)
Favoured 94.48
Allowed 4.97
Outliers 0.55
a Values in parentheses are for highest-resolution shell
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manipulation, we tested the binding of SLFN13-N with in vitro
transcribed human tRNAGly or tRNASer (human tRNA tran-
scripts were used in the functional assays throughout this paper,
unless otherwise specified). tRNAGly is a typical 74-nt tRNA
molecule, whereas the 85-nt tRNASer has a longer variable loop
(Supplementary Table 1). In the electrophoretic mobility shift
assay (EMSA), we did not observe a clear migration shift of tRNA
for rSLFN13-N or hSLFN13-N. Interestingly, the tRNA seemed
degraded as the concentration of both SLFN13-N increased
(Supplementary Fig. 3a). Further experiments confirmed that
rSLFN13-N preferably digested tRNAs over other types of nucleic
acids in a protein concentration-dependent manner, and this
activity also relied on Mn2+/Mg2+ (Fig. 2a–c; Supplementary
Fig. 3b, c and Supplementary Table 2). Regarding other soluble
SLFN N′-domains that could be purified in our experiments, the
tRNA-cleaving feature was observed for hSLFN13-N and
mSLFN8-N, but not for hSLFN5-N. Moreover, hSLFN13-N
exhibited the highest cleaving efficiency and specificity among
these proteins (Fig. 2d). We expanded the target tRNA types, and
found that hSLFN13-N was more active than rSLFN13-N in
almost all cases (Supplementary Fig. 3d, Supplementary Table 1).
In addition, purified full-length mSLFN1 lacks nucleolytic activity
on given tRNAs (Supplementary Fig. 3e). These results exemplify
the diversity of SLFNs in tRNA manipulation.
The processing pattern of SLFN13-N for tRNAs. hSLFN13,
mSLFN8 and rSLFN13 share a common cleavage product (spe-
cified as primary product, Fig. 2d), and this product appeared for
all tRNA targets (Supplementary Fig. 3d), suggesting that the
cleavage by SLFN13 takes place first on a specific site of tRNAs.
To figure out the exact cleavage site, we generated tRNASer
molecules with differentially modified termini and tested them in
the digestion assay. Extension of the 5′ end by a guanosine (5′-G-
tRNASer, V1) led to larger product bands, whereas shortening of
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Fig. 1 Structure of rSLFN13 N′-domain. a Schematic representation showing the organisation of crystallised rSLFN1314–353 based on full-length rSLFN13. NE
denotes the N-terminal extension coded by the DNA sequence from the vector; BD denotes bridging domain. Elements for rSLFN1314–353 are assigned
according to the structure. Borders of each element are indicated by residue numbers. b Structure of rSLFN1314–353. Domains of rSLFN1314–353 are indicated
and coloured as in a. Disordered loops are shown as dashed lines. The Zn2+ ion in the zinc finger is shown as a grey sphere. α-helices and β-strands of each
domain are specified. The size of the valley is indicated. c The topology diagram of rSLFN1314–353. Secondary structural elements were not drawn to scale.
Elements of rSLFN1314–353 are named and coloured as in a. A dashed line is drawn to indicate the pseudo-symmetry of rSLFN1314–353. d Interactions
between BD and N-lobe. Side chains of involved residues are shown in the same colour as the domains they belong to. e Interactions between BD and C-
lobe. Note the similarity with d. f Extra interactions between BD and C-lobe. Note the CCCH-type zinc finger
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the 3′ end (tRNASer−3′-ΔGCCA, V3) had no effect (Fig. 2e). This
means the original 5′ end of tRNASer was preserved in the pri-
mary product, and the cleavage site is close to the 3′ end. When
two extra bases (GC) were added to the 5′ end of the tRNASer (5′-
GC-tRNASer, V2) which extended the acceptor stem from 7 to 9
bp, the tRNA became resistant to SLFN13. Once the GCCA motif
at the 3′ end was removed from this tRNA molecule (5′-GC-
tRNASer−3′-ΔGCCA, V4), it became cleavable again (Fig. 2e).
These results indicate that the length of the paired bases of the
tRNA acceptor stem is important for the selectivity of SLFN13. By
comparing the migration rate of SLFN13-digested tRNASer with
designated markers in electrophoresis assay, we found that the
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Fig. 2 Endoribonuclease activity of SLFN13-N. a Dose-dependent and time-dependent tRNA digestion by rSLFN13-N in the presence of Mg2+. rSLFN131–353
of indicated concentrations were incubated with [α-32P]-labelled human tRNAGly, human tRNASer or rat tRNASer (rtRNASer) for 5, 15 and 30min. b
rSLFN13-N preferably cleaves tRNA. ssDNA/ssRNA single-stranded DNA/RNA, dsDNA/dsRNA double-stranded DNA/RNA. c Analysis of divalent cations
as cofactor of rSLFN13-N for tRNA digestion. 500 nM rSLFN131–353 was incubated with [α-32P]-labelled tRNASer for 30min. Four different divalent cations
were individually tested. d Cleavage assay for different SLFN-N proteins. 250 nM rSLFN131–353, mSLFN81–359, hSLFN131–355 or hSLFN512–334 was individually
incubated with [α-32P]-labelled tRNASer. Note that hSLFN13-N shows highest nucleolytic efficiency over human tRNASer. e Cleavage assay for rSLFN13-N
on acceptor stem variants. Modifications of the variants are specified. 500 nM rSLFN131–353 was used in each reaction. f tRNA cleavage pattern of SLFN13-
N. The primary cleavage products from tRNASer by rSLFN131–353 and hSLFN131–355 were compared with in vitro transcribed tRNASer that lacks 3′-terminal
10 nt (tRNASer−3′-Δ10 nt) or 11 nt (tRNASer−3′-Δ11 nt), and portrayed to the left. The migration of two truncated tRNASer markers is indicated by dashes
lines. g Proposed primary cleavage site of SLFN13-N. The sequence of human tRNASer is used here as representative
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primary cleavage takes place on the acceptor stem of the substrate
tRNA and most likely removes 11 nt at the 3′-terminus (Fig. 2f,
g). For some tRNAs, a ‘secondary’ cleavage product could be
observed, which seems to be derived from further digestion by
SLFN13-N as it never appeared alone (Fig. 2a–e; Supplementary
Fig. 3b–d). According to the size and migration feature of this
product, we infer that the secondary cleavage takes place on the
T-loop, which dissevers another 11 or 12 nt from the primary
product (Supplementary Fig. 3f).
To further investigate the selectivity of SLFN13-N on tRNAs,
we assayed several types of tRNAs from various species for
SLFN13-N cleavage. Most of the tRNAs were able to be digested
by hSLFN13-N, whereas rSLFN13-N seemed more active to those
tRNAs with longer variation loops (Supplementary Fig. 4a–d and
Supplementary Table 1). Interestingly, both hSLFN13-N and
rSLFN13-N lacked the endoribonuclease activity on tRNASec that
possesses a 9-bp acceptor stem (Supplementary Fig. 4c, d). This
result supports our finding that the length of acceptor stem is
critical for the selectivity of SLFN13-N (Fig. 2e).
SLFN13-N is structurally distinct from other RNases. The
observed tRNA-cleaving activity of SLFN13-N prompted us to
scrutinise its structure again. rSLFN13-N shows no apparent
homology to known protein families, including other tRNA-
cleaving enzymes in archaea (EndA), bacteria (colicin E5) or
eukaryotes (PaT in yeast and angiogenin in mammals)26–29. In
addition, rSLFN13-N also differs from Drosha30 and Dicer31
which also contain pseudo-dimeric catalytic domains (Supple-
mentary Fig. 5a). We compared rSLFN13-N structure with
existing crystal structures using the Dali server32. The ouput top
hits included several bacterial proteins and the aligned region
covered only one lobe of SLFN13 (Supplementary Fig. 5b). Apart
from the uncharacterised proteins, we noticed that the lobes of
rSLFN13-N are topologically related to the DNase I-like sub-
domain of the E.coli endoribonuclease RNase E33. The central
four-stranded β-sheet and surrounded α-helices of SFLN13-N C-
lobe could be substantially aligned to the DNase I-like subdomain
with a root mean square deviation (rmsd) of 3.14 Å, although the
latter has two extra β-strands (Fig. 3a; Supplementary Fig. 5c, d).
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Fig. 4 SLFN13-N cleaves native tRNA and rRNA. a, b Cleavage assay of hSLFN13-N (a) and rSLFN13-N (b) on native tRNAs in the presence of Mg2+. Small
RNA-293T denotes total small RNA extracted from 293T cells that is mainly constituted of tRNAs. tRNASer and tRNAGly were used as controls to indicate
molecular weight. c Cleavage assay of different SLFN-Ns on native tRNAs. d–f Cleavage assay on specific native tRNAs. The substrates and products were
identified by Northern blot using [γ-32P]-labelled probes targeting tRNASer (d), tRNAGly (e) or tRNALys (f). g Cleavage assay for hSLFN13-N on 5S rRNA.
5S rRNA and products were identified by Northern blot. h Cleavage assay on native rRNAs. 4 μg total RNA extracted from 293T cells was used for each
reaction, which mainly contains rRNAs
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The DNase I-like subdomain is a component of the RNase E
catalytic domain that forms a homotetramer33. Within this tet-
ramer, the DNase I subdomain dimerises and cleaves two single-
stranded RNA at both sides of the dimer (Supplementary Fig. 5e).
Compared with RNase E, native rSLFN13-N is a monomer in
solution (Supplementary Fig. 2a), and has distinct overall archi-
tecture and substrate preference. Thus, although bearing putative
evolutional traces from the bacterial RNases, SLFN13-N repre-
sents a novel class of endoribonuclease.
Critical regions of SLFN13-N for tRNA cleavage. Surface elec-
trostatic potential analysis of rSLFN13-N revealed two positively
charged patches inside the valley, whose width is exactly suitable
for accommodating base-paired RNA (Fig. 3b). Substitution of
conserved charged residues (Lys38, Arg39, Lys42, Arg217,
Lys224, Lys276) to alanine resulted in reduced nucleolytic activ-
ity, suggesting that rSLFN13-N may embrace base-paired RNA
within its valley (Fig. 3c). Apart from the positively charged
patches, a negatively charged area formed by conserved Glu205,
Glu210 and Asp248 of the C-lobe is also observed at the rim of
the valley (Fig. 3b; Supplementary Figs 6 and 7a, b). The three-
carboxylate triad is reminiscent of the catalytic residues of bac-
terial endoribonucleases involved in RNA processing, such as
RNase E and RNase III, which coordinate a hydrated Mg2+,
possibly for the nucleophilic attack on the scissile phosphate in
the RNA backbone33,34 (Fig. 3d). Mutating any of the three
residues diminished the nucleolytic activity of rSLFN13-N and
hSLFN13-N (Fig. 3c, e). Even at elevated enzyme concentration,
E205A and E210A mutants were absolutely inactive, which
differed from other single-point mutants (D34A, E47A, E84A,
E96A, E146A, D193A, E221A, E229A, E249A, D259A, E323A,
D350A) regarding exposed and relatively conserved aspartates or
glutamates (Fig. 3c, e; Supplementary Fig. 7c–e). This result
demonstrates, that Glu205 and Glu210 are pivotal residues for the
endonucleolytic activity of SLFN13-N. In addition, this plausible
active site appears only in the C-lobe but not in the N-lobe
(Supplementary Fig. 6), suggesting that SLFN13 cleaves only on
one site of base-paired RNA. This is in accordance with the
results of tRNA cleavage assays (Fig. 2e).
Mechanistic model of tRNA cleavage by SLFN13-N. Based on
the biochemical analysis, we propose that SLFN13-N clamps the
tRNA acceptor stem and cleaves in a site-specific and sequence-
independent manner, which is likely controlled by the interplay
between the inner shape of the valley and the tertiary structure of
the tRNAs (Fig. 3f). To illustrate this special mechanism, we
generated a structural model of SLFN13-N–tRNA complex
(Fig. 3g). In this model, the acceptor stem of the tRNA is perfectly
docked in the valley of SLFN13-N, where the protruding posi-
tively charged residues support the tRNA backbone, and putative
active site of SLFN13-N is right next to the predicted cleavage site
between the 65th and 66th nucleotide of tRNA. The 5′ end of
tRNA is tightly packed in the valley, leaving insufficient space for
an extra base (Fig. 3h). This may explain why SLFN13-N does not
cleave the V2-tRNASer that has a 9-bp acceptor arm (Fig. 2e).
This reaction would cause the loss of the CCA tail, hence the
amino-acylation of tRNA molecules.
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SLFN13 restricts cellular tRNA and rRNA. To understand
whether SLFN13-N is able to digest natural tRNAs carrying
various post-transcriptional modifications, total tRNAs isolated
from HEK-293T (293T) cells or HeLa cells were applied to
cleavage assays. When incubated with hSLFN13-N, mSLFN8-N
or rSLFN13-N, the total tRNA showed a degradation pattern
similar to the in vitro experiments in a protein concentration-
dependent manner (Figs 2a, 4a–c; Supplementary Fig. 8a–c).
Northern blot assays confirmed that several types of tRNA were
susceptible to hSLFN13-N and rSLFN13-N digestion (Fig. 4d–f;
Supplementary Table 3). In addition, SLFN13-N was able to
digest the 5S, 18S and 28S rRNA extracted from 293T cells or
HeLa cells (Fig. 4g, h; Supplementary Fig. 8d). We surmise, that
SLFN13-N cuts rRNAs at base-paired regions that are topologi-
cally similar to the acceptor stem of tRNAs.
Next, we investigated hSLFN13 in vivo. Although several
other Schlafen family members of subgroup III were reported to
carry a nuclear localisation signal (NLS)22, hSLFN13 does not
seem to have any NLS (Supplementary Figs 1a and 6).
Overexpressed hSLFN13 showed a preference for cytoplasmic
distribution in 293T cells and HeLa cells, therefore, it should be
accessible to mature tRNAs and ribosomes (Fig. 5a; Supple-
mentary Fig. 8e). Indeed, the tRNA and rRNA levels in
hSLFN13-expressing cells were markedly reduced, which is
apparently associated with its nucleolytic activity (Fig. 5b;
Supplementary Fig. 8f). We then investigated the effect of
hSLFN13 on protein synthesis based on fluorescent non-
canonical amino acid labelling (FUNCAT). Newly synthesised
proteins were labelled using homopropargylglycine (HPG) and
detected via click chemistry (Fig. 5c). In hSLFN13-transfected
293T cells, the amount of newly synthesised proteins was greatly
diminished (Fig. 5d, e). These results prove that hSFLN13 can
disrupt translational machinery and retard protein synthesis by
restricting cytoplasmic tRNA and rRNA.
SLFN13 restricts HIV in a nucleolytic activity-dependent
manner. Several subgroup III SLFNs are suggested to restrict
different viruses21,23. While hSLFN13 was reported to moderately
inhibit influenza virus, it is intriguing as to whether SLFN13 also
inhibits other types of viruses. Expression of SLFN13 was not
inducible by IFNɑ/β/γ treatment in 293T cells, but could be sti-
mulated by the infection of VSV-G pseudotyped HIV-1 (HIVVSV-
G) (Supplementary Fig. 9a, b). To confirm whether SLFN13 is
capable to restrict HIV, we transfected 293T cells with pNL4-3-
ΔEnv-EGFP (encoding essential HIV-1 proteins but the coding
sequence for HIV-1 Envelope was partially replaced by the cDNA
of EGFP) and pCMV-VSV-G (encoding the vesicular stomatitis
virus G glycoprotein, or VSV-G that serves as a surrogate viral
envelope protein), and measured the titre of VSV-G pseudotyped
HIV-1 (HIVVSV-G) produced from these cells in the presence of
hSLFN13/hSLFN13-N constructs (Fig. 6a). After being trans-
fected with wild-type (WT) hSLFN13, these cells failed to yield
HIVVSV-G titre, indicating the restriction of HIV (Fig. 6b). In
agreement with this, knock-down of SLFN13 dramatically wea-
kened HIV resistance of 293 cells (Fig. 6c; Supplementary Fig. 9c,
d). Apart from HIV, we also tested antiviral activity of SLFN13 on
viruses belonging to Herpesviridae and Flaviviridae. hSLFN13
failed to confer efficient resistance against herpes simplex virus
(HSV), and only moderately restricted Zika virus (Supplementary
Fig. 9e, f).
The nucleolytic-deficient mutations E208A and E213A
dramatically decreased the anti-HIV activity of hSLFN13, while
the less destructive mutant D251A remained highly active
(Fig. 6b). This anti-HIV tendency of hSLFN13 mutants is
congruent with their behaviours in the tRNA cleavage assays
(Figs 3e, 4a–c; Supplementary Fig. 7d), manifesting the crucial
role of hSLFN13's nucleolytic activity in HIV restriction.
Moreover, hSLFN13-N also efficiently reduced viral titre,
whereas hSLFN13-N(E208A) and hSLFN13-N(E213A) showed
much weaker anti-HIV activity compared to their full-length
counterparts (Supplementary Fig. 9g), suggesting that the
SWADL domain and/or helicase domain may also contribute
to the anti-HIV activity of hSLFN13.
SLFN13 blocks synthesis of viral proteins. To discern whether
hSLFN13 reduced the number or the viability of the released
virus, we measured viral protein and viral RNA (vRNA) levels in
the supernatant of hSLFN13/hSLFN13-N-transfected, HIVVSV-G-
producing cells. Extracellular concentration pattern of p24 capsid,
total vRNA or unspliced vRNA was consistent with the titre
results, suggesting that hSLFN13 diminished the number of
released viral particles (Fig. 6d–f; Supplementary Fig. 9h–j and
Supplementary Table 4). Moreover, hSLFN13/hSLFN13-N sup-
pressed the fluorescence from 293T cells transfected with viral
vector pNL4-3-ΔEnv-EGFP (Fig. 6g; Supplementary Fig. 9k),
which was strong evidence for the disrupted synthesis of viral
proteins. To clarify whether this observation resulted solely from
overall protein synthesis arrest caused by hSLFN13 or hSLFN13-
N, we compared the fluorescence of various EGFP-containing
plasmids co-transfected with hSLFN13/hSLFN13-N in 293T cells.
Plasmids with HIV promoter were obviously more susceptible
than the control plasmid (Supplementary Fig. 9l, m), illustrating
the preference of hSLFN13 over HIV-related protein synthesis.
This preference is possibly resulted from the cleavage by SLFN13
on the HIV-derived sequences of the transcripts, as they contain
stem loops which structurally resemble the SLFN13-targeting
regions of tRNAs (Fig. 2g). In addition, we also checked whether
hSLFN13 hinders HIVVSV-G infection (Fig. 6i). Although
293T cells pre-transfected with hSLFN13/hSLFN13-N showed a
decreased GFP level (Fig. 6i; Supplementary Fig. 9n), this result
may be attributable to the restriction of global protein synthesis.
Thus, it is currently tentative to conclude SLFN13 affects the
infection of HIV.
Discussion
Our study has revealed SLFN13 as a novel type of eukaryotic
tRNA/rRNA endoribonuclease with several features. First, its
unique pseudo-dimeric U-pillow-shaped architecture allows
for the docking of base-paired RNA. Second, SLFN13 seems to
lack the discrimination over tRNA types but relies on the
recognition of the secondary or tertiary structure. Third,
according to the effects of overexpressed SLFN13 in transla-
tional control of cell lines, it is possible that upon certain
cellular stresses, induced SLFN13 inhibits protein synthesis by
directly digesting cytoplasmic tRNA and rRNA, so as to realise
a fast stress response. Fourth, SLFN13 is so far the only
eukaryotic endoribonuclease that has been proven to pre-
ferably cleave at the acceptor stem of mature tRNAs. Many
other cytosolic tRNA processors target the anti-codon loop,
such as stress-induced mammalian angiogenin15,35 and yeast
Rny1p14, as well as E. coli PrrC and colicin D/E5 involved in
the bacterial defence system9,36–38. In bacteria, the secreted
bacterial toxin CdiA family involved in contact-dependent
growth inhibition was also reported to cut the acceptor stem of
certain tRNAs39. However, unlike SLFN13, the in vitro
nucleolytic activity of CdiA family proteins is dependent on the
association with elongation factor Tu (EF-Tu) and the presence
of GTP40. According to these properties, we propose a novel
nomenclature for SLFN13: RNase S13.
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The nucleolytic activity of hSLFN13 is crucial for its anti-HIV
potency. The cleavage of cytoplasmic tRNA and rRNA by
hSLFN13 may cause global translation inhibition that suppresses
both viral replication and cell viability to confine viruses (Fig. 6j).
A similar mechanism was discovered for the suicidal tRNase PrrC
in E. coli, which cleaves its own tRNALys in response to bacter-
iophage T4 infection36. This may explain a recent observation
that marmoset SLFN11 blocks synthesis of both host and viral
proteins41. In addition, tRNA degradation may also negatively
impact the reverse transcription of HIV which requires host
tRNALys as the primer42.
We observed the preference of SLFN13 for blocking synthesis of
viral proteins as compared to endogenous ones. As the key
determinant of tRNA cleavage by SLFN13 is the secondary struc-
ture but not the anti-codon sequence, we assume that the pre-
ference for HIV protein synthesis of SLFN13 may not stem from
the codon-usage-based mechanism reported for SLFN1123. On the
other hand, HIV genome contains rich stem loop regions that are
essential for the replication and packaging of the virus43,44.
SLFN13 may directly digest some of these stem loops to specifically
disrupt the life cycle of HIV. The tRNA-derived fragments (tRFs)
have been suggested to constitute a new group of functional none-
coding RNAs13. These tRFs, generated by certain tRNases
including angiogenin, were found to be involved in cellular stress
response and cancer progression by means of regulating tran-
scription and translation in cells45–48. This mechanism might also
apply to the tRNA fragments generated by SLFN13 which retards
protein synthesis. Overall, more targets of SLFN13 need to be
identified in order to understand its detailed antiviral mechanism.
We found that hSLFN5-N and mSLFN1, albeit both retaining
the key catalytic residues (corresponding to Glu205 and Glu210
of rSLFN13), did not cleave the given tRNAs (Fig. 2d). Compared
to rSLFN13, hSLFN5 lacks two positively charged residues that
were proven critical for tRNA/rRNA digestion (i.e. Lys42 and
Arg217 of rSLFN13), whereas the equivalents of rSLFN13 Arg39,
Lys42 and Lys276 are absent in mSLFN1 (Supplementary Fig. 6).
In contrast, hSLFN13, mSLFN8, as well as rabbit SLFN14 which
was reported active for tRNA/rRNA cleavage24, showed higher
sequence consistency in the positively charged patches (Fig. 3b;
Supplementary Fig. 6). We conclude that the distribution of
positively charged residues inside the valley of the N′-domain
may define the capability and selectivity in tRNA/rRNA cleavage,
as well as the antiviral spectrum, for different SLFNs. Although
more enzymatic studies and characterisation of the SWADL
domain and helicase domain are needed for different SLFNs, it is
conceivable that tRNA/rRNA manipulation may be a hallmark of
the Schlafen family, and the difference in their N′-domains may
be one of the factors that define the functional diversity of these
proteins.
Regarding the functional diversity of the Schlafen family, other
than the restriction of viruses, the inhibition of cell proliferation
has been suggested as a prominent character for many members.
For example, hSLFN5 was found to negatively regulate the
anchorage-independent growth and invasion of malignant mel-
anoma cells19. Mouse SLFN1, SLFN2, SLFN3 and SLFN5 were all
shown as proliferation suppressors when individually expressed
in NIH3T3 murine fibroblasts, T cells or various human tumour
cells18,20,25,49–51. In addition, mouse SLFN2 was also reported to
play an important role in maintaining the quiescence of T cells
and monocytes during immune response52. Given the prevalence
of the N′-domain in SLFNs and the apparent relationship
between the translational level and cell proliferation/growth, it is
tempting to speculate that SLFNs exert the aforementioned
functions through translational regulation. Thus, our study pro-
vides valuable clues for investigating the functional mechanisms
of the versatile Schlafen family in the future.
Methods
Molecular cloning. cDNAs of SLFN-N constructs, including those for crystal-
lisation (rSLFN1314–353) and cleavage assays (rSLFN131–353, mSLFN81–359,
hSLFN131–355 and hSLFN512–334), were individually cloned into a modified pET28
vector. Details of major constructs are illustrated in Supplementary Fig. 1b. For
eukaryotic expression, full-length hSLFN13 (hSLFN13FL) and hSLFN131–355 were
individually cloned into the pCAGGS vector with an N-terminal Flag-tag. Indi-
cated mutants were prepared based on corresponding recombinant plasmids by
site-directed mutagenesis. In the fluorescence assay, pEGFP-C1 vector was used to
generate recombinant plasmid expressing GFP fused hSLFN13FL.
Protein expression and purification. Recombinant proteins containing an N-
terminal His6-tag followed by a cleavage site for PreScission protease (PSP) were
expressed in Escherichia coli (E. coli) Rosetta (DE3). Transformed bacteria were
cultured at 37 °C in Terrific Broth (TB) medium before induced with 0.1 mM
isopropyl-1-thio-β-d-galactopyranoside at an OD600 nm of 0.6, and grown over-
night at 16 °C. Cells were lysed in 50 mM Tris-HCl, pH 8.2, 300 mM NaCl, 30 mM
imidazole, 1 μMDNase I, 1 mM phenylmethanesulfonylfluoride (PMSF) and 2 mM
β-mercaptoethanol (β-ME) using a cell disruptor (JNBIO) and subjected to cen-
trifugation at 40,000 × g for 50 min. The supernatant was filtered and applied to the
first Ni-NTA column (GE Healthcare) equilibrated with binding buffer 1 con-
taining 20 mM Tris-HCl, pH 8.2, 300 mM NaCl, 30 mM imidazole and 2 mM β-
ME. After washed with wash buffer containing 20 mM Tris-HCl, pH 8.2, 300 mM
NaCl, 70 mM imidazole and 2 mM β-ME, proteins were eluted with elution buffer
containing 20 mM Tris-HCl, pH 8.2, 300 mM NaCl, 300 mM imidazole and 2 mM
β-ME. Except for rSLFN1314–353, the eluted protein was incubated with glutathione
S-transferase (GST)-fused PSP to remove the His6-tag and dialysed overnight
against binding buffer 2 containing 20 mM Tris-HCl, pH 8.2, 300 mM NaCl and 2
mM β-ME. After dialysis, PSP was removed using a GST column. The protein was
re-applied to the second Ni-NTA column equilibrated with binding buffer 2.
Binding buffer 1 was used to elute the proteins which were subsequently loaded
onto a Superdex200 16/60 column (GE Healthcare) equilibrated with gel filtration
buffer containing 20 mM Tris-HCl, pH 8.2, 150 mM NaCl and 1 mM dithiothreitol
(DTT). The proteins were eluted in a discrete peak corresponding to a molecular
mass of approximately 40 kDa. For rSLFN1314–353, the protein was directly applied
to gel filtration using a Superdex200 16/60 column (GE Healthcare) equilibrated
with buffer containing 20 mM HEPES, pH 7.0, 150 mM NaCl and 1 mM DTT after
elution from the first Ni-NTA. The proteins were eluted in a discrete peak cor-
responding to a molecular mass of approximately 80 kDa. Cell lysis and protein
purification were both performed at 4 °C. The yields of SLFN13-N mutants used
for endoribonuclease study were comparable with that of wide-type protein. The
selenomethionine (SeMet) derivative of rSLFN1314–353 was insoluble. We therefore
made an alanine screening mutagenesis for each methionine of rSLFN1314–353 to
look for soluble constructs, which resulted in rSLFN1314–353(M179A) as an optimal
candidate. SeMet-substituted rSLFN1314–353(M179A) was expressed as previously
described53 and purified as native rSLFN1314–353, except that 5 mM instead of 2
mM β-ME was used in first Ni-NTA purification, and 2 mM instead of 1 mM DTT
was used in gel filtration.
Protein crystallisation. Crystallisation trials by the sitting-drop vapour-diffusion
method were performed at 4 °C. rSLFN1314–353 (18 mgml−1 in buffer containing
20 mM HEPES, pH 7.0, 150 mM NaCl and 1 mM DTT) was mixed with an equal
volume of reservoir solution containing 20% PEG6000, 100 mM MES, pH 6.5 and
850–950 mM lithium chloride. Crystals of the native protein appeared after 5 days
and grew to a maximum size in 10 days. Crystals of SeMet-substituted
rSLFN1314–353(M179A) were obtained in the same conditions as native
rSLFN1314–353. For data collection, crystals of native and Se-Met protein were
flash-frozen in the reservoir solution containing extra 20% PEG200.
Structure determination. X-ray diffraction data set of native rSLFN1314–353 was
collected from a single crystal at beamline BL19U1 of the Shanghai Synchrotron
Radiation Facility (SSRF), and one data set of SeMet-substituted
rSLFN1314–353(M176A) at the selenium peak wavelength was collected at beamline
BL17U1 of SSRF54. Data sets were processed with the XDS suite55 and HKL-2000
programme suite56. Initial phases were obtained by the single-anomalous disper-
sion method and refined using Phaser57. In the calculated electron density, the
main chains and many side chains were clearly traceable. Owing to the high quality
of the density map, an initial model was manually built with COOT58, where the
positions of 31 selenium atoms in the asymmetric unit were used to assign the
sequences of four peptide chains. The model was further refined with Refmac59 and
Phenix60. Structural validation was carried out using MolProbity61. Structural
illustrations were prepared using the PyMOL Molecular Graphic Systems (version
0.99, Schrödinger LLC; http://www.pymol.org/). X-ray data collection and refine-
ment statistics can be found in Extended Data Table 1. The Ramachandran sta-
tistics determined by PROCHECK62 are as follows: 94.48% in favoured region,
4.97% allowed, 0.55% outlier. To confirm the incorporation of zinc, X-ray fluor-
escence scan over the rSLFN1314–353 crystal was carried out at SSRF, and the
excitation energy was 9679 eV.
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tRNA substrate preparation. Preparation of tDNA transcription template and
in vitro transcription of tRNAs was performed as previously described63. To pre-
pare [α-32P]-labelled tRNA, 250 ng µl−1 tDNA transcription template was mixed
with 2 mM of each NTP, 3.4 μM [α-32P] ATP (6000 Ci/mmol, PerkinElmer), 20
mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM MgCl2, 5 mM DTT, 1 mM sper-
midine and 0.3 µM T7 RNA polymerase at 37 °C for 1 h. The labelled tRNA
product was subsequently purified with a Zymo-Spin IC Column (Zymo Research)
and eluted with 200 μl TE buffer containing 20 mM Tris-HCl, pH 8.0 and 1 mM
EDTA. The eluted tRNA was aliquoted and stored at −20 °C if not immediately
used. Sequences of the tRNA transcripts used in this study were listed in Supple-
mentary Table 1.
EMSA. rSLFN131–353 or hSLFN131–355 of increasing concentrations was indivi-
dually incubated with 5 μM tRNAGly(CCC) or tRNASer(UAG) in buffer containing
40 mM Tris-HCl, pH 8.5, 20 mM KCl, 2 mM MgCl2, 2 mM DTT and 5% glycerol
for 30 min at 25 °C. After the incubation, each sample was mixed with loading
buffer containing 3% glycerol and 0.05% bromophenol blue before loaded onto a
6% native polyacrylamide gel containing 40 mM Tris-acetate, pH 8.5. The gel was
pre-run at 4 °C for 45 min at 14.0 V cm−1 with running buffer containing 40 mM
Tris-acetate, pH 8.5. After electrophoresis the gel was stained with ethidium bro-
mide (EB) and visualised by UV light.
Cell culture. Unless otherwise specified, HeLa, HEK-293, HEK-293T, Vero and
A549 cells were individually maintained at 37 °C in high glucose Dulbecco's
modified Eagle medium (DMEM) supplemented with 10% fatal calf serum, 100 U
ml−1 penicillin and 100 μg ml−1 streptomycin. Albopictus C6/36 cells, used for
propagation of the Zika virus, were grown in DMEM supplemented with 10% fetal
calf serum at 28 °C. All cell lines are free of mycoplasma. HeLa, 293, 293T and
A549 cell lines have been authenticated by genotyping.
In vitro cleavage assay. For substrate screening assay, 2 µM rSLFN131–353 was
individually incubated with 1 µM each ssDNA, ssRNA, dsDNA, dsRNA, DNA/
RNA duplex, stem-loop RNA or tRNASer in the cleavage buffer containing 40 mM
Tris-HCl, pH 8.0, 20 mM KCl, 4 mM MgCl2 and 2 mM DTT for 30 min at 37 °C.
The sequences of the nucleic acids used in this experiment are summarised in
Supplementary Table 2.
For cleavage assays on in vitro transcribed tRNAs, either [α-32P]-labelled or
non-labelled tRNA transcripts were used as substrates. For radiolabelled tRNAs to
be detected by autoradiography, protein of increasing concentration was mixed
with labelled tRNA (>1 × 104 cpm) in the cleavage buffer at 37 °C. Aliquots were
taken at different time points as indicated, and the reaction was terminated by
adding 2× formamide gel-loading buffer (95% w/v formamide, 50 mM EDTA). The
cleavage products were analysed by electrophoresis at 250 V by a 12% denaturing
urea-polyacrylamide gel (Urea-PAGE) containing 7.5 M urea with 1× TBE (89 mM
Tris, 89 mM borate and 2 mM EDTA) as the running buffer. All the gels were
exposed to a phosphorimager plate overnight before scanned with a Typhoon
scanner (GE Healthcare). For non-labelled tRNA substrates, 1 µM protein was
mixed with 2 µM tRNASer in the cleavage buffer at 37 °C. Subsequent experimental
procedures were the same as those for labelled tRNA substrates. After
electrophoresis, the gel was stained with EB and visualised by UV light.
For cleavage assays on native RNAs, total small RNA was extracted from
cultured 293T or HeLa cells using mirVana miRNA Isolation kit (Ambion)
following the small RNA isolation protocol. An aliquot of 1 µM or indicated
amount of protein was incubated with 0.5 μM control tRNAs or 50 ng µl−1 total
small RNA in the cleavage buffer for 30 min or indicated time at 37 °C. The
cleavage products were analysed by electrophoresis. Total RNA was extracted from
cultured 293T or HeLa cells using TRI Reagent (Sigma-Aldrich). Protein of
indicated concentrations was incubated with 20 ng µl−1 tRNASer control, or 0.4 µg
µl−1 (for EB staining) or 1 µg µl−1 (for Northern blot) total RNA in the cleavage
buffer for 30 min at 37 °C. Cleavage products were analysed by electrophoresis, and
then either stained with EB or subjected to Northern blot.
Northern blot analysis. The cleavage reaction to be analysed by Northern blot was
denatured by heating at 80 °C for 10 min in a 2× formamide gel-loading buffer,
followed by quick chill on ice. These samples were separated by Urea-PAGE and
subsequently electroblotted onto the Hybond N+ membranes (GE Healthcare) at
250 mA for 3 h in 1× TBE buffer. After air-dried for 10 min, the RNA samples were
fixed to the membrane by UV cross-linking. The membrane was pre-hybridised in
the hybridisation buffer containing 0.2% Ficoll (Mr= 40,000), 0.2% polyvinyl-
pyrrolidone (Mr= 40,000), 0.2% bovine serum albumin (BSA), 50% formamide,
50 mM Tris-HCl, pH 7.5, 1 M NaCl, 0.1% sodium pyrophosphate and 0.1 mgml−1
denatured salmon sperm DNA at 42 °C for 3 h. The hybridisation was carried out
at 42 °C overnight in the presence of [γ-32P]-ATP (6000 Ci/mmol, PerkinElmer)
DNA oligonucleotide probes which were previously end-labelled using T4 poly-
nucleotide kinase. The probe sequences were complementary to the 5′ end of
specified tRNAs and 5S rRNA (see Supplementary Table 3 for details). The
hybridised membrane was washed three times with 1× SSC buffer (150 mM NaCl,
15 mM sodium citrate, pH 7.0 and 0.1% SDS) at 42 °C for 30 min each. The blots
were exposed to a phosphorimager plate overnight before scanned with a Typhoon
scanner (GE Healthcare).
Western blot analysis. Following antibodies were used in for Western blot assays
in this paper: anti-Flag antibody (Sigma-Aldrich, F1804, 1:1000 used), anti-β-
tubulin antibody (ProteinTech, 66240-1-Ig, 1:2000 used), anti-Lamin B1 (Pro-
teinTech, 66095-1-Ig, 1:1000 used), anti-GAPDH (60004-1-Ig, 1:5000 used), HRP-
conjugated anti-mouse secondary antibody (Cell Signaling Technology, 7076,
1:3000 used) and HRP-conjugated anti-rabbit secondary antibody (ProteinTech,
SA00001-2, 1:3000 used). The cell pellets after transfection were lysed in ice-cold
lysis buffer (20 mM HEPES, pH 7.9, 1 mM EDTA, 400 mM NaCl, 10 mM KCl, 1%
Nonidet P-40 and 20% Glycerol) containing protease inhibitor cocktail and PMSF.
After centrifugation at 12,000 × g for 15 min, the supernatant separated by 10%
SDS-PAGE, transferred to PVDF membranes (Thermo Scientific). After an 1 h
incubation with blocking buffer (5% BSA), the membrane was incubated with
corresponding antibodies overnight at 4 °C. The membrane was washed and
incubated with HRP-conjugated secondary antibodies. The membranes were
washed again, developed with ECL Western Blotting Detection Reagents (Thermo
Scientific) and visualised with ChemiDocTM Touch Imaging System (Bio-Rad).
Subcellular localisation analysis. For fluorescence assay, 293T cells and HeLa
cells grown on round glass slides in 24-well plates were transfected with pEGFP-
C1-hSLFN13FL using Lipofectamine 2000 (Thermo Scientific). After 24 h, the cells
were fixed with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH
7.4) at room temperature for 10 min and washed with PBS for three times. Fixed
cells were stained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for
nuclear staining and then mounted in antifade mounting medium (Thermo Sci-
entific). Slides were viewed with an FV1000 fluorescent microscope (Olympus).
For analysis by Western blot, 293T cells were transfected with pCAGGS-
hSLFN13FL. After 24 h, cells were collected, and NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific) was used to separate nuclear and cytosolic
fractions after cell lysis according to manufacturer’s instructions. The two fractions
were then individually subjected to Western blot analysis.
Quantification of cellular RNA. A total of 1 × 105 293T cells transfected with
empty pCAGGS vector, pCAGGS-hSLFN13FL or pCAGGS-hSLFN13FL(E213A)
were individually sorted by flow cytometry. Artificial spike-in RNA (1000 nt) was
added to the sorted cells as control before total RNA was extracted using TRI
Reagent (Sigma-Aldrich). Total RNA was pooled by size and quantified using
Bioanalyzer and RNA 6000 Pico Kit (Agilent) following the manufacturer’s
protocol.
FUNCAT assay and click chemistry. 293T cells transfected with empty pCAGGS
vector, pCAGGS-hSLFN13FL or pCAGGS-hSLFN13FL(E213A) were re-transfected
with corresponding plasmids 12 h after initial transfection. 36 h after initial
transfection, cells of 80% confluence were washed twice in pre-warmed PBS and
then starved in serum-free DMEM lacking methionine (SFM) for 1 h (Thermo
Scientific). Following the starvation, 4 mM L-HPG (Click Chemistry Tools) or 4
mM methionine was appended into SFM for a 4-h pulse as described earlier64.
For flow cytometry analysis, the collected cells were fixed in 0.5 ml of 1% PFA in
PBS for 15 min on ice and permeabilised in PBS containing 0.1% saponin (Sigma-
Aldrich) for 5 min at room temperature as described65. After labelled by copper-
catalysed azide-alkyne cycloaddition (CuAAC), cells were washed and resuspended
in PBS, and immediately analysed by flow cytometry. As an additional negative
control, 100 μg ml−1 translational elongation inhibitor cycloheximide (CHX,
Sigma-Aldrich) was added 30 min before HPG incorporation. Cy5 fluorescence
signal was detected using a CytoFLEX flow cytometer (Beckman Coulter).
For SDS-PAGE analysis, cells were collected and lysed in ice-cold lysis buffer
(20 mM HEPES, pH 7.9, 1 mM EDTA, 400 mM NaCl, 10 mM KCl, 1% Nonidet P-
40 and 20% Glycerol) containing protease inhibitor cocktail and PMSF. Protein
concentration was determined using Pierce BCA Protein Assay Kit (Thermo
Scientific). HPG incorporated protein lysates were labelled selectively with Cy5-
conjugated azide by CuAAC66,67. The click reaction was performed following the
protocol from Click Chemistry Protein Reaction Buffer Kit (Click Chemistry
Tools): 70 μl soluble protein lysates (1.5–4 μg μl−1) incorporated with HPG or
methionine were sequentially mixed with 90 µl Reaction Buffer, 1 μl Cy5-azide (8
mM), 10 µl Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 100 mM), 10 µl
CuSO4 (20 mM) and 10 µl sodium ascorbate (300 mM). The mixture was rotated
end-over-end in dark for 30 min at room temperature to generate a stable triazole
adduct, and then subjected to 1× Laemmli buffer. After heated at 70 °C for 10 min,
the samples were resolved by SDS-PAGE and imaged using a pharos FXTM Plus
Molecular Imager (Bio-Rad). Loading consistency was confirmed by staining the
gels with Coomassie Blue after fluorescent imaging.
Assay for HIV, HSV and Zika virus production. All HIV-related assays in this
study were based on HIV-1. To analyse HIV retrovirus production, pNL4-3-ΔEnv-
EGFP vector and pCMV-VSV-G packaging vector were transfected into the
293T cells which were pre-transfected with empty pCAGGS vector, pCAGGS-
hSLFN13FL, pCAGGS-hSLFN131–355 or corresponding mutants using
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Lipofectamine 2000 (Thermo Scientific) according to the manufacturer’s instruc-
tions. The old culture medium was replaced with fresh culture medium at 6 h post-
transfection. Subsequently, the supernatants were collected at 48 h post-
transfection and cleared by centrifugation. The amount of (infectious) virus par-
ticles in the supernatants was determined via infection assay, quantitative (q)PCR
of viral RNA (total RNA and unspliced RNA) and HIV p24 ELISA (Supplementary
Table 4). For infection assays, pre-plated 293T cells were infected with serially
diluted supernatants for 6 h. At 24 h post-infection, the 293T cells were examined
for GFP expression by flow cytometry. HIV viral RNA was extracted from the virus
supernatants and quantified. The amount of p24 was measured using an HIV-1
p24 ELISA Kit (Clonetech) according to the manufacturer’s instructions. The
expression of intracellular GFP was measured by flow cytometry.
For HIV package assays in 293 cells, pNL4-3-ΔEnv-EGFP vector and pCMV-
VSV-G packaging vector were transfected into the 293 cells which were pre-
transfected with scramble-siRNA, SLFN13-siRNA#1 or SLFN13-siRNA#2. The
supernatants were collected at 48 h post-transfection and measured by infecting
pre-plated 293T cells. The mRNA level of hSLFN13 was measured by qPCR
(primers are listed in Supplementary Table 4).
The GFP fused HSV is a gift from Prof. G. F. Gao. For virus preparation, pre-
plated Vero cells were infected with HSV (MOI= 0.03) in serum-free DMEM for 2
h. 48–72 h after the infection, the Vero cells became suspension and were collected.
The virus-containing lysates were generated by freeze/thaw cycles followed by
centrifugation at 4000 rpm for 15 min. For HSV infection and production assay,
pre-plated 293T cells were infected with HSV (MOI= 0.02) after transfected with
pCAGGS-hSLFN13 and related mutants for 2 h. The supernatants were collected
18 h after infection and diluted to infect pre-plated Vero cells for plaque formation
and HSV titre determination.
For Zika virus production, albopictus C6/36 cells were infected with wide-type
strain MR766 at 28 °C and virus supernatants were collected 5 days after infection.
For Zika infection and production assay, A549 cells overexpressing pCAGGS-
hSLFN13 and corresponding mutants were rinsed once with PBS, and infected with
virus for 2 h at 37 °C. 48 h after infection, the supernatants were collected and
diluted to infect pre-plated Vero cells for plaque assay.
Assay for HIV infection. HIVVSV-G was prepared by transfecting 293T cells with
pNL4-3-ΔEnv-EGFP and pCMV-VSV-G using Lipofectamine 2000 (Thermo Sci-
entific). The cell culture medium was collected and cleared as described above.
Cells to be tested were infected for 6 h. At 24 h post-infection, GFP expression was
measured to determine the relative infection efficiencies.
Determination of viral RNA level. Virion supernatants were lysed and homo-
genised with TRIzol Reagent (Thermo Scientific) following the manufacturer’s
protocol. Viral protein and DNA were removed by centrifugation at 4 °C for 15
min at 12,000 × g, and vRNA was extracted from the upper aqueous phase and
subsequently reverse transcribed using PrimeScript RT reagent Kit (TaKaRa). The
concentrations of total vRNA and unspliced vRNA were individually determined
by qPCR with CFX96 Real-Time System (Bio-Rad) using SYBR Premix ExTaq Kit
(TaKaRa). Primers used in qPCR are listed in Supplementary Table 4.
Data availability. The X-ray crystallographic coordinates and structure factor files
for rSLFN13-N has been deposited in the Protein Data Bank (PDB) under acces-
sion number 5YD0. All other data generated or analysed during this study are
included in this published article, and are available from the corresponding author
upon reasonable request.
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